<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073811424799</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073811424799</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Child With Night Blindness</article-title>
<subtitle>Preventing Serious Symptoms of Refsum Disease</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kohlschütter</surname>
<given-names>Alfried</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811424799">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073811424799"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santer</surname>
<given-names>René</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073811424799">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lukacs</surname>
<given-names>Zoltan</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0883073811424799">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Altenburg</surname>
<given-names>Christiane</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0883073811424799">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kemper</surname>
<given-names>Markus J.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0883073811424799">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rüther</surname>
<given-names>Klaus</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff6-0883073811424799">6</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073811424799">
<label>1</label>Clinic for Degenerative Brain Diseases, Children’s Hospital, University Medical Center Eppendorf, Hamburg, Germany</aff>
<aff id="aff2-0883073811424799">
<label>2</label>Division of Metabolism, Children’s Hospital, University Medical Center Eppendorf, Hamburg, Germany</aff>
<aff id="aff3-0883073811424799">
<label>3</label>Diagnostic Laboratory, University Medical Center Eppendorf, Hamburg, Germany</aff>
<aff id="aff4-0883073811424799">
<label>4</label>Lipid Clinics, Department of Internal Medicine, University Medical Center Eppendorf, Hamburg, Germany</aff>
<aff id="aff5-0883073811424799">
<label>5</label>Division of Pediatric Nephrology, Children’s Hospital, University Medical Center Eppendorf, Hamburg, Germany</aff>
<aff id="aff6-0883073811424799">
<label>6</label>Department of Ophthalmology, St Gertrauden-Krankenhaus, Berlin, Germany</aff>
<author-notes>
<corresp id="corresp1-0883073811424799">Alfried Kohlschütter, MD, Children’s Hospital, University Medical Center Hamburg–Eppendorf, Martinistr. 52, 20246 Hamburg, Germany Email: <email>kohlschuetter@uke.uni-hamburg.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<fpage>654</fpage>
<lpage>656</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>9</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Refsum disease is a genetic progressive neurological disorder caused by neurotoxic phytanic acid, a nutritional component patients are unable to metabolize. Symptoms include retinopathy, polyneuropathy, ataxia, and deafness. They are variable and rarely recognized before adulthood. The authors report the case of a 14-year-old girl diagnosed because of night blindness. They treated her with a phytanic acid–poor diet and extracorporeal lipid apheresis. They used different methods over a 30-month period. Thereafter, the patient was treated with diet only. Membrane filtration and heparin-induced extracorporeal low-density lipoprotein precipitation apheresis were well tolerated. Withdrawal of phytanic acid was studied quantitatively. During a 5-year period, blood phytanic acid levels decreased to a noncritical range. The patient remained free of ophthalmological and neurological progression for a total observation of 12 years. Early diagnosis and effective measures to keep the phytanic acid load low can probably prevent the serious sequelae of Refsum disease. Developing a method for newborn screening is desirable.</p>
</abstract>
<kwd-group>
<kwd>neurodegenerative disease</kwd>
<kwd>retinopathy</kwd>
<kwd>phytanic acid</kwd>
<kwd>Refsum</kwd>
<kwd>lipid apheresis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Refsum disease (OMIM 266500) is a rare genetic neurodegenerative disorder that leads to retinopathy, polyneuropathy, ataxia, and deafness. Damage to the nervous system is caused by phytanic acid, a neurotoxic fatty acid that patients accumulate in their tissues from nutritional sources because of a deficient peroxisomal α-oxidation of the molecule.<sup>
<xref ref-type="bibr" rid="bibr1-0883073811424799">1</xref>
</sup> A diet low in phytanic acid can reduce the tissue load when followed reliably.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811424799">2</xref>
</sup>
</p>
<p>Refsum disease in children has only rarely been reported, probably because of its mostly subtle clinical manifestation. Acute infantile presentations, however, have been reported.<sup>
<xref ref-type="bibr" rid="bibr3-0883073811424799">3</xref>,<xref ref-type="bibr" rid="bibr4-0883073811424799">4</xref>
</sup> We report the treatment of a young girl diagnosed with mild neurological but severe ophthalmological symptoms of Refsum disease. Upon reaching her majority, the patient consented to the publication of her case.</p>
<p>After a period of diet therapy proved inadequate to reduce phytanic acid blood levels effectively, we chose the more aggressive approach of lipid apheresis to reduce the risk of neurological progression. Two different methods of lipid apheresis were tested for tolerance and efficiency.</p>
<sec id="section1-0883073811424799">
<title>Case Report and Methods</title>
<p>A healthy 14-year-old girl went to see an ophthalmologist because of an inability to see well in dim light. At the age of 10 years, her skin had been noticed to be scaly, and at 12 years, a moderate hearing loss at high frequencies had been noted. Ophthalmological examination revealed a retinopathy and anosmy, a constellation suspicious of Refsum disease. This diagnosis was confirmed by elevated phytanic acid plasma levels and by demonstration of homozygosity for the novel <italic>PHYH</italic> mutation c.830C&gt;A predicting the amino acid exchange p.A277E within a highly conserved region of the PHYH protein.<sup>
<xref ref-type="bibr" rid="bibr5-0883073811424799">5</xref>
</sup>
</p>
<p>Apart from night blindness, visual field constriction, and anosmy, the patient felt well and was free of signs and symptoms of any disease. Neurography revealed a subclinical demyelinating polyneuropathy.</p>
<p>Phytanic acid levels in the patient’s whole plasma and in plasma lipid fractions were measured sequentially over more than 5 years (<xref ref-type="fig" rid="fig1-0883073811424799">Figure 1</xref>), using gas chromatographic analysis of fatty acids from total lipids.<sup>
<xref ref-type="bibr" rid="bibr6-0883073811424799">6</xref>
</sup> Following a phytanic acid–poor diet for 18 months decreased phytanic acid plasma levels from 8% of total fatty acids to 5% (normal &lt;0.05%). As body fat represents a large reservoir of phytanic acid, the danger of phytanic acid toxicity persists for a long time. We therefore instituted monthly extracorporeal venovenous lipid apheresis for 30 months, using different methods. Membrane differential filtration<sup>
<xref ref-type="bibr" rid="bibr7-0883073811424799">7</xref>,<xref ref-type="bibr" rid="bibr8-0883073811424799">8</xref>
</sup> was used and well tolerated for 18 months. For organizational reasons, this procedure was substituted by direct adsorption of lipoproteins (DALI)<sup>
<xref ref-type="bibr" rid="bibr9-0883073811424799">9</xref>
</sup> for 2 treatment sessions and then stopped because of an apparent hypersensitivity reaction. For the remaining 10 months of the apheresis treatment period, heparin-induced extracorporeal low-density lipoprotein precipitation (HELP)<sup>
<xref ref-type="bibr" rid="bibr10-0883073811424799">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073811424799">11</xref>
</sup> was used, which was well tolerated.</p>
<fig id="fig1-0883073811424799" position="float">
<label>Figure 1.</label>
<caption>
<p>Phytanic acid plasma levels in a young patient with Refsum disease under dietary treatment and under a combined therapy of diet and monthly lipid apheresis, measured over 5 years. Levels of phytanic are shown as absolute concentration (black symbols) and as proportion of total fatty acids of plasma (empty symbols). Broken lines are respective linear trend lines. Symbols connected by vertical lines represent values measured before and after a lipid apheresis session.</p>
</caption>
<graphic alternate-form-of="fig1-0883073811424799" xlink:href="10.1177_0883073811424799-fig1.tif"/>
</fig>
<p>Removal of phytanic acid from circulating blood was assessed repeatedly by measuring phytanic acid content in whole plasma and the lipid fractions removed. With membrane filtration and HELP apheresis methods, the proportional reduction of phytanic acid during a single session of 2 to 3 hours was most pronounced in the low-density lipoprotein fraction and was in the range of 70% to 80%. The average removal of phytanic acid per treatment session was about 100 mg.</p>
<p>Over time, the patient’s phytanic acid plasma levels (Figure 1) slowly fell into a range no longer considered dangerous so that therapy was reduced to diet alone. During a further 7-year follow-up (to age 26 years), ophthalmological findings remained completely stable. The subclinical polyneuropathy also stabilized with a (statistically not significant) tendency toward normalization.</p>
</sec>
<sec id="section2-0883073811424799">
<title>Discussion</title>
<p>These observations in a young Refsum patient illustrate some important points:</p>
<list list-type="order">
<list-item>
<p>Refsum disease can be suspected early, before serious irreparable neurological damage has occurred. In the present case, the combination of night blindness, visual field constriction, and the reduced capacity to smell led to the correct diagnosis.</p>
</list-item>
<list-item>
<p>A diet poor in phytanic was reliably maintained over many years in an adolescent, as shown by its effect on phytanic acid plasma levels. It was associated with the lack of progress of any neurological symptoms. An effective diet for Refsum disease is easier to maintain than the diet for many other inborn errors of metabolism.</p>
</list-item>
<list-item>
<p>Although lipid apheresis has been used to remove phytanic acid from the circulation in critically ill adults with very high plasma levels of the toxic compound,<sup>
<xref ref-type="bibr" rid="bibr1-0883073811424799">1</xref>,<xref ref-type="bibr" rid="bibr8-0883073811424799">8</xref>
</sup> 2 different methods of apheresis (extracorporeal membrane differential filtration and heparin-induced low-density lipoprotein precipitation) were well tolerated by the young girl presented and were equally effective in removing phytanic acid. The evidence for the justification of plasma apheresis in Refsum disease, however, is still scarce. Randomized controlled trials are difficult to perform because of the long observation periods needed in such a chronic (and rare) disease. Therefore, reports of single cases and small series may provide more evidence for the value of lipid apheresis in the treatment of these patients.</p>
</list-item>
<list-item>
<p>Refsum disease would be a potential target for newborn screening, as its dire consequences can probably be fully prevented by diet. Unfortunately, no screening method has been developed yet.</p>
</list-item>
</list>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was done at the Children’s Hospital and the Lipid Clinics of the Department of Internal Medicine, University Medical Center Eppendorf, Hamburg, Germany. Partial results were presented at the annual meeting of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Hamburg, Germany, September 2007. We thank our patient for her cooperation and for her consent to publication.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073811424799">
<p>AK provided the case history with clinical and biochemical studies and drafted manuscript. RS prepared molecular genetic results. ZL prepared biochemical results. CA performed HELP and DALI lipid apheresis. MJK performed membrane filtration lipid apheresis. KR diagnosed the patient and provided a discussion of Refsum disease.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073811424799">
<p>The authors declared no potential conflicts of interests with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073811424799">
<p>The authors received no financial support for the research and/or authorship of this article. </p>
</fn>
<fn fn-type="other" id="fn4-0883073811424799">
<p>This study was approved by the review board of Children’s Hospital, University Medical Center Hamburg-Eppendorf.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073811424799">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wanders</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Skjeldal</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>. Refsum disease</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Scriver</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D</given-names>
</name>
</person-group>, eds. <source>Metabolic and Molecular Bases of Inherited Disease (MMBID)</source>. <edition>8th ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2005</year>:<fpage>3303</fpage>–<lpage>3321</lpage>.</citation>
</ref>
<ref id="bibr2-0883073811424799">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldwin</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Gibberd</surname>
<given-names>FB</given-names>
</name>
<name>
<surname>Harley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sidey</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Feher</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Wierzbicki</surname>
<given-names>AS</given-names>
</name>
</person-group>. <article-title>The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2010</year>;<volume>81</volume>:<fpage>954</fpage>–<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr3-0883073811424799">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mortimer</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Faed</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Styles</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peart</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>A child with Refsum’s disease: successful treatment with diet and plasma exchange</article-title>. <source>Dev Med Child Neurol</source>. <year>1989</year>;<volume>31</volume>:<fpage>92</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr4-0883073811424799">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herbert</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>PT</given-names>
</name>
</person-group>. <article-title>Phytanic acid alpha-oxidase deficiency (Refsum disease) presenting in infancy</article-title>. <source>J Inherit Metab Dis</source>. <year>1994</year>;<volume>17</volume>:<fpage>211</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr5-0883073811424799">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Waterham</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Wanders</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7)</article-title>. <source>Hum Mutat</source>. <year>2004</year>;<volume>23</volume>:<fpage>209</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr6-0883073811424799">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hübner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lindner</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Claussen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kohlschütter</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Membrane fluidity and lipid composition of rat small intestinal brush-border membranes during postnatal maturation</article-title>. <source>Biochim Biophys Acta</source>. <year>1988</year>;<volume>939</volume>:<fpage>145</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr7-0883073811424799">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Julius</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Metzler</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pietzsch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fassbender</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Klingel</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP</article-title>. <source>Int J Artif Organs</source>. <year>2002</year>;<volume>25</volume>:<fpage>1180</fpage>–<lpage>1188</lpage>.</citation>
</ref>
<ref id="bibr8-0883073811424799">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Straube</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gäckler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muselmann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kingreen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Klingel</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Membrane differential filtration is safe and effective for the long-term treatment of Refsum syndrome: an update of treatment modalities and pathophysiological cognition</article-title>. <source>Transfus Apheresis Sci</source>. <year>2003</year>;<volume>29</volume>:<fpage>85</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr9-0883073811424799">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosch</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Practical aspects of direct adsorption of lipoproteins from whole blood by DALI LDL-apheresis</article-title>. <source>Transfus Apheresis Sci</source>. <year>2004</year>;<volume>31</volume>:<fpage>83</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr10-0883073811424799">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walzl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walzl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Heparin-induced extracorporeal fibrinogen/LDL precipitation (HELP): a promising regimen for the treatment of vascular diseases</article-title>. <source>Angiology</source>. <year>1997</year>;<volume>48</volume>:<fpage>1031</fpage>–<lpage>1036</lpage>.</citation>
</ref>
<ref id="bibr11-0883073811424799">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Schuff-Werner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Eisenhauer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Helmhold</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stix</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seidel</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels</article-title>. <source>Chem Phys Lipids</source>. <year>1994</year>;<fpage>67</fpage>–<lpage>68</lpage>:<volume>315-321</volume>.</citation>
</ref>
</ref-list>
</back>
</article>